These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16401755)

  • 1. Apolipoprotein e genotype modifies the phenotype of Alzheimer disease.
    Schott JM; Ridha BH; Crutch SJ; Healy DG; Uphill JB; Warrington EK; Rossor MN; Fox NC
    Arch Neurol; 2006 Jan; 63(1):155-6. PubMed ID: 16401755
    [No Abstract]   [Full Text] [Related]  

  • 2. [The apolipoprotein E gene and Alzheimer disease phenotype].
    Kurz A; Egensperger R; Lautenschlager N; Haupt M; Altland K; Graeber MB; Müller U
    Z Gerontol Geriatr; 1995; 28(3):195-9. PubMed ID: 7664194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E genotype and cognition in the very old.
    Altstiel LD; Greenberg DA; Marin D; Lantz M; Mohs R
    Lancet; 1997 May; 349(9063):1451. PubMed ID: 9164326
    [No Abstract]   [Full Text] [Related]  

  • 4. No association between apolipoprotein E genotype and late-onset depression in Alzheimer's disease.
    Cantillon M; Harwood D; Barker W; St George-Hyslop P; Tsuda T; Ekatarina R; Duara R
    Biol Psychiatry; 1997 Jan; 41(2):246-8. PubMed ID: 9018400
    [No Abstract]   [Full Text] [Related]  

  • 5. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study.
    Stewart R
    Neurology; 2001 Dec; 57(11):2149. PubMed ID: 11739854
    [No Abstract]   [Full Text] [Related]  

  • 6. Context-specific memory and apolipoprotein E (ApoE) epsilon 4: cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease.
    Levy JA; Bergeson J; Putnam K; Rosen V; Cohen R; Lalonde F; Mirza N; Linker G; Sunderland T
    J Int Neuropsychol Soc; 2004 May; 10(3):362-70. PubMed ID: 15147594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological soft signs are associated with APOE genotype, age and cognitive performance.
    Lautenschlager NT; Wu JS; Laws SM; Almeida OP; Clarnette RM; Joesbury K; Wagenpfeil S; Martins G; Paton A; Gandy SE; Förstl H; Martins RN
    J Alzheimers Dis; 2005 Aug; 7(4):325-30. PubMed ID: 16131735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E epsilon4 allele and clinically defined vascular depression.
    Rigaud AS; Latour F; Moulin F; Forette F; Traykov L; Boller F
    Arch Gen Psychiatry; 2002 Mar; 59(3):290-1. PubMed ID: 11879173
    [No Abstract]   [Full Text] [Related]  

  • 9. [Genotype and phenotype of apolipoprotein E in patients with Alzheimer's disease in Castille and Leon].
    Cacho J; Breñas T; González C; Arroyo T; Arcaya J; García R; Guerrero AL; Navajo JA; García C; González Buitrago JM
    Neurologia; 1997 Nov; 12(9):384-8. PubMed ID: 9471175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E and Alzheimer disease.
    Growdon JH
    Arch Neurol; 1998 Aug; 55(8):1053-4. PubMed ID: 9708953
    [No Abstract]   [Full Text] [Related]  

  • 11. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease.
    Roses AD
    Ann Neurol; 1995 Jul; 38(1):6-14. PubMed ID: 7611727
    [No Abstract]   [Full Text] [Related]  

  • 12. Cognitive change and the APOE epsilon 4 allele.
    Deary IJ; Whiteman MC; Pattie A; Starr JM; Hayward C; Wright AF; Carothers A; Whalley LJ
    Nature; 2002 Aug; 418(6901):932. PubMed ID: 12198535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of apolipoprotein E genotype on biochemical markers of Alzheimer's disease.
    Schenk D; Lieberburg I; Motter R; Seubert P
    Ann N Y Acad Sci; 1996 Dec; 802():92-100. PubMed ID: 8993488
    [No Abstract]   [Full Text] [Related]  

  • 14. Apolipoprotein E genotype and the rate of decline in probable Alzheimer disease.
    Corder EH; Lannfelt L; Basun H
    Arch Neurol; 1996 Nov; 53(11):1094-5. PubMed ID: 8912482
    [No Abstract]   [Full Text] [Related]  

  • 15. APOE-dependent PET patterns of brain activation in Alzheimer disease.
    Scarmeas N; Anderson KE; Hilton J; Park A; Habeck C; Flynn J; Tycko B; Stern Y
    Neurology; 2004 Sep; 63(5):913-5. PubMed ID: 15365149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nature throws curveballs: APOE and nonlinear decline in Alzheimer disease.
    Camicioli R; Kryscio R
    Neurology; 2005 Dec; 65(12):1855-6. PubMed ID: 16380605
    [No Abstract]   [Full Text] [Related]  

  • 17. Prefrontal activation patterns in subjects at risk for Alzheimer disease.
    Petrella JR; Lustig C; Bucher LA; Jha AP; Doraiswamy PM
    Am J Geriatr Psychiatry; 2002; 10(1):112-3. PubMed ID: 11790642
    [No Abstract]   [Full Text] [Related]  

  • 18. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease.
    Levy ML; Cummings JL; Fairbanks LA; Sultzer DL; Small GW
    Biol Psychiatry; 1999 Feb; 45(4):422-5. PubMed ID: 10071711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls.
    Kramer G; van der Flier WM; de Langen C; Blankenstein MA; Scheltens P; Stam CJ
    Clin Neurophysiol; 2008 Dec; 119(12):2727-32. PubMed ID: 18848805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of APOE genotype on clinical phenotype in Alzheimer disease.
    Borroni B; Di Luca M; Padovani A
    Neurology; 2007 Feb; 68(8):624; author reply 624. PubMed ID: 17310043
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.